Value & Access Summit Moderator & Speakers
- Jane Barlow, MD, MPH, MBA
- Randy Burkholder
- Amitabh Chandra, PhD
- Ronda Copher, PhD
- Clifford Goodman, PhD
- Mehb Khoja, FSA, MAAA
- Kimberly Lenz, PharmD, MBA, FAMCP
- Brenden O’Hara, RPh, BCACP
- Gail Ryan, PharmD
- Todd D. Sorensen, PharmD
- Troy Trygstad, PharmD, MBA, PhD
- Kimberly Westrich, MA
Additional speakers to come.
Clifford Goodman, PhD, is a senior vice president at The Lewin Group. He has more than 30 years of experience in health technology assessment, evidence-based health care, health economics, and aspects of health care innovation, regulation, and payment. Dr. Goodman often serves as a health policy issues moderator and facilitator of expert panels and advisory boards. He served as chair of the CMS Medicare Evidence Development & Coverage Advisory Committee and president of the professional society, Health Technology Assessment International (HTAi). In 2022, he was recognized by HTAi with The David Banta Distinguished Career award. He received his Doctorate in Philosophy from The Wharton School of the University of Pennsylvania and degrees from Georgia Tech and Cornell.
Dr. Jane Barlow is a clinical and strategic executive consultant with more than 25 years of health care leadership experience. She is chief clinical officer of Real Endpoints, a market access company, serves as senior advisor to the Tufts Center for Biomedical Innovation New Drug Development Paradigms (NEWDIGS), and is an independent board director for ContraFect Corporation, Viracta Pharmaceuticals, and Sera Prognostics. Dr. Barlow focuses on evaluating the economic impact and value of pharmaceuticals and diagnostics to aid in defining access and coverage strategies with a focus on outcomes and innovative contracting.
Dr. Barlow previously held senior leadership positions at CVS Health, Medco Health Solutions, and IBM. Her diverse background also includes positions with the U.S. Air Force, Veteran’s Affairs, industry and private practice.
Dr. Barlow attended medical school at Creighton University and completed her residency training in occupational medicine at Johns Hopkins University. She holds master's degrees in business administration and public health and is a Certified Physician Executive with a certificate in health information technology from the American College of Physician Executives. Dr. Barlow is board-certified in occupational medicine and is a fellow of both the American College of Occupational and Environmental Medicine and the American College of Preventive Medicine.
Randy Burkholder is the vice president of Policy and Research at the Pharmaceutical Research and Manufacturers of America. Mr. Burkholder leads PhRMA's work in initiating policy solutions to drive biopharmaceutical innovation and high-quality, patient-centered health care. Mr. Burkholder represents PhRMA at federal agencies and advisory bodies, including the Medicare Evidence Development and Coverage Advisory Committee, CMS' Technical Expert Panel on oncology, and the Federal Coordinating Council for Comparative Effectiveness Research. He also is a former member of the Board of Directors of the Personalized Medicine Coalition. He serves on the Steering Committee of the Partnership to Improve Patient Care and the advisory committee for the Turning the Tide Against Cancer initiative.
Mr. Burkholder has over 20 years of experience in health care policy, advocacy, and communications in the medical technology and pharmaceutical industries. Before joining PhRMA, Mr. Burkholder was associate vice president for Public Affairs at AdvaMed, the industry-leading medical device and diagnostics association.
Professor Chandra studies innovation, productivity, pricing and technology in health care, medical malpractice, and disparities in health care. His research has been published in leading journals such as the American Economic Review, Journal of Political Economy, the New England Journal of Medicine, JAMA, and Health Affairs. Professor Chandra has testified before the US Senate and the US Commission on Civil Rights, and has served as special commissioner on the Massachusetts Special Commission on Provider Price Reform. He is a member of the Congressional Budget Office’s (CBO’s) Panel of Health Advisors, a research associate at the National Bureau of Economic Research (NBER), and an elected member of the National Academy of Medicine and the National Academy of Social Insurance. He is the recipient of the Upjohn Institute Dissertation Award, the Kenneth Arrow Award for best paper in health economics, the Eugene Garfield Award for Economic Impact on Medical Research, the National Institute for Health Care Management (NIHCM) research award, and the American Society of Health Economists’ ASHE Medal.
Dr. Ronda Copher is the Senior Director of Customer & Portfolio Value Generation within Value, Access & Pricing at Bristol-Meyers Squibb. Her organization develops and executes innovative solutions to ensure patient access with particular emphasis on education and collaboration opportunities that address health equity and population health.
Dr. Copher has 10+ years of patient centric activities that include evidence generation strategies and value communications. She has worked in Global and US environments managing product life cycle, stake holder collaborations and value assessments. Ronda has worked with health systems, commercial payers, GPOs and employer groups building connections that demonstrate the value of therapies and the importance of access for patients.
Dr. Copher holds a Master’s and PhD from the University of Minnesota and completed her undergraduate education at Rutgers University in Sociology and Economics.
Mehb Khoja is the Chief Actuary at BCS Financial and a large claim expert. He has worked on all facets of stop loss and reinsurance including product development, pricing, filing, capital considerations, and distribution. Mehb has consulted employers, health plans, stop loss carriers, reinsurers, and pharmaceutical manufacturers with a particular focus on cell/gene therapy. Since joining BCS in 2020, Mehb has developed new solutions for employers and health plans that solve for gene therapy risk in a cost-efficient manner. Prior to joining BCS, Mehb was president of medical risk managers, the largest stop-managing general underwriter in the country. Prior to that role, Mehb had various strategy, actuarial, and benefit consulting roles at Mercer and Milliman. He is a frequent speaker at industry events, a volunteer with the Society of Actuaries, and has published several pieces on the employer stop-loss market. Mehb is a Fellow of the Society of Actuaries and a Member of the American Academy of Actuaries.
Kimberly Lenz, PharmD, MBA, FAMCP, is the senior pharmacy director in the office of clinical affairs, MassHealth’s clinical unit. In this role, she serves the Massachusetts Medicaid program in overseeing the pharmacy benefit. As a leader in the office of clinical affairs, she oversees all clinical and operational components of the Medicaid Pharmacy benefit. Her clinical areas of focus include appropriate opioid prescribing, substance use disorder, transitions of care, and a multidisciplinary approach to complex disease states.
Dr. Lenz is a member of the Institute for Clinical and Economic Review's New England Comparative Effectiveness Public Advisory Council. She is also active at AMCP-serving or chairing several committees. She received her Doctor of Pharmacy degree from the University of Connecticut, completed a residency at St. Louis Children’s Hospital, obtained her MBA at the University of Massachusetts, and is an AMCP fellow. She is also an assistant professor in family medicine and community health at the University of Massachusetts Chan Medical School.
Brenden O’Hara, current President of the Carolinas AMCP Affiliate and active member of the Professional Practice Committee, also serves AMCP as the Diplomat for Campbell. Additionally, he is active in the North Carolina Association of Pharmacists and the American Pharmacists Association and has held leadership positions at the State and National levels.
After graduating from the Albany College of Pharmacy, he began his career in community pharmacy. His commitment to managed care commenced in 2009 at the Physicians Pharmacy Alliance, where he served as a clinical pharmacist and provider relations director. He then transitioned to Ateb, a computer software company, and developed programs for community pharmacies related to Stars, medication synchronization, and the appointment-based model. He began at Blue Cross NC in 2015, and currently works on value-based programs implementing pharmacy quality and cost of care programs.
Brian O'Mahony is the chief executive of the Irish Haemophilia Society and the former president of the World Federation of Hemophilia and the European Haemophilia Consortium. O'Mahony is an active board member of the Irish Blood Transfusion Service, serving as chairperson of both their research and scoliosis design committee.
A fellow of the Academy of Clinical Science and Laboratory Medicine (Ireland) and the Institute of Biomedical Sciences (UK), O'Mahony is a well-established researcher, authoring over 80-peer reviewed articles published in scientific journals. He has post-graduate qualifications in Management and Occupational Health and Safety and currently serves as an assistant adjunct Professor in Health Service Management at Trinity College in Dublin.
Gail Ryan is the director of pharmaceutical transformation at Point32Health, the parent organization of Harvard Pilgrim Health Care and Tufts Health Plan, two of New England’s most iconic nonprofit health care companies. Point32Health, which serves over 2 million patients, is an industry leader in innovation and value-based contracting. As a clinical pharmacist with 20 years of managed care experience, Gail’s practice has spanned the pharmacy benefit, medical drug policy, trend analysis, cost management initiatives, and clinical innovation. In her current role and through partnerships with multi-stakeholders, she is driving equitable access to high-quality, transformative therapies while addressing emerging trends, challenges, and financial risk. Gail holds a Bachelor of Science degree and a Doctor of Pharmacy from the Massachusetts College of Pharmacy and Health Sciences.
Dr. Sorensen is a professor and senior executive associate dean at the College of Pharmacy, University of Minnesota, and executive director for the Alliance for Integrated Medication Management. His work concentrates on identifying strategies that facilitate clinical practice development and developing change management and leadership skills in student pharmacists, pharmacy residents, and practitioners. For more than 20 years, his scholarly activities have focused on building collaborations with health care delivery organizations and health care payers to implement clinical strategies delivered by pharmacists that improve health outcomes. This work is grounded in diffusion of innovation theory, principles of quality improvement, and the discipline of implementation science.
Troy is the executive director of CPESN USA, a clinically integrated network of community-based pharmacy networks that works to improve the quality and effectiveness of care by aligning participating pharmacies with the workflows and payment reform incentives of physicians and other healthcare providers. He also serves as the Vice President of Pharmacy Provider Partnerships for Community Care of North Carolina, an organization providing wrap-around population health management support for nearly 2,000 primary care practices.
Troy possesses over twenty years of experience with multi-disciplinary care teams and intervention development under alternative payment and support models. He was the project director for a Center for Multi-year Medicare & Medicaid Innovation Award that tested new models of payment and pharmacy connectivity to primary care providers. Troy co-founded the Pharmacy Home Project in 2007 which combined more than 50 different medical list contexts into a single portal to be easily accessible for health care providers in multiple settings of care.
Troy proudly practices in a community pharmacy setting on nights and weekends. He served recently as a board member for the American Pharmacists Association Foundation and the Pharmacy Quality Alliance, as well as Editor-in-Chief of Pharmacy Times. Troy received Doctor of Pharmacy and Master of Business Administration degrees from Drake University and a PhD in pharmaceutical outcomes and policy from the University of North Carolina at Chapel Hill.
Kimberly Westrich, MA, is the director of value and access strategy at Xcenda. She leads projects relating to value assessment frameworks, market access, value demonstration, and health economics and outcomes research.
Ms. Westrich is an expert on health technology and value assessment, value-based agreements, quality measures, accountable care organizations, high-deductible health plans, and value-based insurance design, and has authored numerous research and policy publications appearing in a variety of leading health journals.
Before joining Xcenda, Ms. Westrich was the vice president of health services research at the National Pharmaceutical Council (NPC) and served as the organizational liaison to ICER. Ms. Westrich holds a Master of Arts degree in Economics from Northwestern University and a Bachelor of Arts degree in Economics from the College of William and Mary.